Dendreon was another biotech company that presented to investors last week. The highlights were:
1) Product Focus is on Oncology (Cancer)
2) 270 employees
3) Main product is Provenge (Prostate Cancer treatment)
4) Provenge is designed for men who have had other treatments fail and can be used in place of chemotherapy
5) A study indicates Provenge leads to a significant improvement in survival rate
6) Neuvenge - in pipeline as a treatment for breast cancer
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment